UBS Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $22
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $22.
UBS analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $22.